Mainz Biomed and Thermo Fisher Scientific Sign a Collaboration Agreement for the Development of Next Generation Colorectal Cancer Screening Product for Global Markets (GlobeNewswire)

Mainz Biomed has partnered with Thermo Fisher Scientific to jointly develop and potentially commercialize a next-generation mRNA-based colorectal cancer screening test. This collaboration will utilize Thermo Fisher’s advanced technologies to enhance Mainz Biomed’s non-invasive tests, which focus on detecting colorectal cancer and precancerous lesions like advanced adenomas. The partnership aims to accelerate global availability of innovative screening solutions, leveraging both companies’ expertise to set new standards in early cancer detection.